Drug Approval | December 16, 2021
U.S. FDA approves Bristol Myers Squibb’s Orencia
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
Subscribe To Our Newsletter & Stay Updated